Quebec Network Réseau Québécoise de l’Amyotrophie Spinale Joins NMD4C as Community of Practice Sub-Group

We are thrilled to announce that the Réseau Québécoise de l’Amyotrophie Spinale (RQAS), a network uniting rehabilitation clinicians across Quebec to advance the care of people with Spinal Muscular Atrophy (SMA) since 2022, has officially become a sub-group Community of Practice of the Neuromuscular Disease Network of Canada (NMD4C).

This marks an exciting milestone for both the NMD4C and RQAS members, offering significant new opportunities and resources.

 

By welcoming the RQAS, the NMD4C gains:

  • A well-established community of practice of 136+ members, including clinicians, researchers, and patient partners.
  • Stronger French-Canadian representation, ensuring diverse perspectives in care, research, and policy.
  • A proven model for clinician-driven collaboration, expanding best practices across neuromuscular diseases.

 

As a sub-group of the NMD4C, the RQAS will benefit from:

  • Greater access to support for research, training, and initiatives to improve neuromuscular care.
  • Enhanced organizational support, streamlining activities for greater efficiency.
  • A broader national network, fostering collaboration, knowledge-sharing, and innovation.

 

Through incorporating RQAS into NMD4C, we will continue our efforts to unify, support, and advance neuromuscular care and research across Canada. We look forward to working together to drive innovation and improve outcomes for individuals with neuromuscular diseases. If you have any questions, contact Community of Practice Manager, Dr Maria Masnata at <>

RQAS logo

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.